Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riboflavin Formulations for Corneal Crosslinking
NCT04897503Phase 3Recruiting
- Sponsor
- Cornea and Laser Eye Institute
- Start
- Apr 2021
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of riboflavin in keratoconus, corneal ectasia, sponsored by Cornea and Laser Eye Institute. Started Apr 2021; status: recruiting.
02
Drugs
riboflavin
03
Conditions
keratoconuscorneal ectasia
Beyond the preview
Go deeper on NCT04897503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04897503.